Umbilical Cord Mesenchymal Stem Cells Treatment For Cardiomyopathy With Cardiomegaly And Heart Failure In Children

ObjectiveTo investigate the therapeutic effect of umbilical cord mesenchymal stem cells(UCMSCs)in the treatment of cardiomyopathy with cardiomegaly and heart failure in children.MethodClinical symptoms,signs and examination results were analyzed after treatment with human umbilical cord mesenchymal stem cells(hUC-MSCs)in 17 cases who were diagnosed as cardiomyopathy with cardiomegaly and heart failure.The main observations were clinical symptoms of heart failure,asymptomatic survival time,number of deaths and survivors,left ventricular ejection fraction,left ventricular short axis shortening rate,left ventricular end diastolic diameter,left ventricular end-systolic diameter,and Ntemrina probarin natriuretic peptide(NT-proBNP)level.The effects and safety of hUCMSCs after treatment were evaluated by analyzing the symptoms,signs,cardiac ultrasound results and laboratory findings of 17 children before and after treatment.ConsequenceasAfter treatment with hUC-MSCs,the clinical symptoms of 17 children were significantly improved,and the activity endurance was enhanced.13 cases(76.5%)achieved asymptomatic survival;left ventricular ejection fraction increased significantly(p<0.05).the levels of NT-pro BNP decreased to different degrees,and cardiac function improved.The cardiac function of 15 cases(88.2%)had improved or no deterioration.The primary arrhythmia improved to varying degrees,the quality of life of the children improved,and no deaths were observed until the end of follow-up.After the treatment of the cells,there was no obvious abnormality in the basic organ function(hepatic and renal function),and there was no obvious abnormality in the local injection site.ConclusionUC-MSCs treatment can improve the clinical symptoms and cardiac function of cardiomyopathy with cardiomegaly and heart failure,and improve quality of life of these children.